A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

People with color vision deficiency -- commonly known as color blindness -- may have a higher risk of mortality from bladder ...

If you have metastatic bladder cancer, you may also be at higher risk for kidney problems, including acute kidney injuries ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...

The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.

Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...